🔎 Trials Near Me

Gara Jalqabaatti › Obesity › North Carolina › Havelock

Qorannoo klinikaalii Obesity Havelock, NC keessatti

Qorannoo 17 Obesity f Havelock fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Namoota walitti qabaa jiraSadarkaa 2
  • Centricity Research - Morehead city /ID# 283264, Morehead City · Miili 15 fagaatti
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07752979

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Namoota walitti qabaa jiraSadarkaa 3
  • Lucas Research, Inc, Morehead City · Miili 15 fagaatti
Umuriin 6 hanga 17 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06672549

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Namoota walitti qabaa jiraSadarkaa 3
  • West Clinical Research, Morehead City · Miili 15 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Namoota walitti qabaa jiraSadarkaa 3
  • Carteret Medical Group, Morehead City · Miili 15 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07392190

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Namoota walitti qabaa jiraSadarkaa 3
  • West Clinical Research, Morehead City · Miili 15 fagaatti
Umuriin 45 hanga 99 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07037433

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Namoota walitti qabaa jiraSadarkaa 2
  • Lucas Research, Inc, Morehead City · Miili 15 fagaatti
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Namoota walitti qabaa jiraSadarkaa 3
  • AURORA-1 Clinical Site, Morehead City · Miili 15 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Namoota walitti qabaa jiraSadarkaa 3
  • AURORA-2 Clinical Site, Morehead City · Miili 15 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Namoota walitti qabaa jiraSadarkaa 3
  • Centricity Research Morehead City Multispeciality, Morehead City · Miili 15 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Namoota walitti qabaa jiraSadarkaa 2
  • Lucas Research, Inc., Morehead City · Miili 15 fagaatti
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06897475

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Namoota walitti qabaa jiraSadarkaa 3Hojjettoota fayyaa simatamoo
  • ACCOMPLISH-2 Research Site, Morehead City · Miili 15 fagaatti
Umuriin 18 hanga 79 · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT07654374

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Namoota walitti qabaa jiraSadarkaa 2
  • Lucas Research, Inc, Morehead City · Miili 15 fagaatti
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT06143956

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Namoota walitti qabaa jiraSadarkaa 3
  • Kailera Clinical Site, Morehead City · Miili 15 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07284901

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Namoota walitti qabaa jiraSadarkaa 3
  • Kailera Clinical Site, Morehead City · Miili 15 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Namoota walitti qabaa jiraSadarkaa 3
  • West Clinical Research, Morehead City · Miili 15 fagaatti
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07684144

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Namoota walitti qabaa jiraSadarkaa 3
  • Kailera Clinical Site, Morehead City · Miili 15 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT07284979

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Namoota walitti qabaa jiraSadarkaa 3
  • Centricity Research Morehead City Specialty, Morehead City · Miili 15 fagaatti
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 27-Hag-2026 · NCT07575399

Qorannoo Obesity magaalota biroo keessatti

Qorannoo biroo Havelock keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.